{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:26:49Z","timestamp":1793924809053,"version":"4.8.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejmech.2026.119341","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T16:18:45Z","timestamp":1789661925000},"page":"119341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Preclinical evaluation of MC1R targeted radiopharmaceuticals using the 203\/212Pb theranostic pair"],"prefix":"10.1016","volume":"320","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0595-8966","authenticated-orcid":false,"given":"Jarred Michael","family":"Scaffidi-Muta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7964-0881","authenticated-orcid":false,"given":"Didier","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwong Ching","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Tieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew David","family":"Abell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119341_bib1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/ITT.S134842","article-title":"Melanoma treatment in review","volume":"7","author":"Domingues","year":"2018","journal-title":"ImmunoTargets Ther."},{"key":"10.1016\/j.ejmech.2026.119341_bib2","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1080\/15384047.2019.1640032","article-title":"Current state of melanoma diagnosis and treatment","volume":"20","author":"Davis","year":"2019","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ejmech.2026.119341_bib3","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1002\/cncr.25191","article-title":"A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma","volume":"116","author":"Croghan","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2026.119341_bib4","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1056\/NEJMra2034861","article-title":"Recent advances in the treatment of melanoma","volume":"384","author":"Curti","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119341_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104276","article-title":"The treatment of advanced melanoma: current approaches and new challenges","volume":"196","author":"Boutros","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ejmech.2026.119341_bib6","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.119341_bib7","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41573-020-0073-9","article-title":"Radiopharmaceutical therapy in cancer: clinical advances and challenges","volume":"19","author":"Sgouros","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119341_bib8","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1158\/1078-0432.CCR-16-2955","article-title":"Radium-223 inhibits osseous prostate cancer growth by dual targeting of cancer cells and bone microenvironment in mouse models","volume":"23","author":"Suominen","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119341_bib9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2967\/jnumed.108.058651","article-title":"MIRD pamphlet no. 22 (Abridged): radiobiology and dosimetry of \u03b1-Particle emitters for targeted radionuclide therapy","volume":"51","author":"Sgouros","year":"2010","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119341_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.692436","article-title":"Revisiting the radiobiology of targeted alpha therapy","volume":"8","author":"Pouget","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.ejmech.2026.119341_bib11","first-page":"404","article-title":"Targeted alpha therapy: current clinical applications","volume":"35","author":"Francisco","year":"2020","journal-title":"Cancer Biother. Rad."},{"key":"10.1016\/j.ejmech.2026.119341_bib12","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jamaoncol.2018.4044","article-title":"Targeted alpha therapy, an emerging class of cancer agents: a review","volume":"4","author":"Group","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejmech.2026.119341_bib13","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s41181-025-00362-7","article-title":"212Pb in targeted radionuclide therapy: a review","volume":"10","author":"Scaffidi-Muta","year":"2025","journal-title":"EJNMMI Radiopharmacy and Chemistry"},{"key":"10.1016\/j.ejmech.2026.119341_bib14","first-page":"6352","article-title":"Characterization of receptors for \u03b1-Melanocyte-stimulating hormone on human melanoma Cells1","volume":"49","author":"Siegrist","year":"1989","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119341_bib15","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1586\/14737140.2.5.485","article-title":"Zevalin: the first radioimmunotherapy approved for the treatment of lymphoma","volume":"2","author":"Grillo-L\u00f3pez","year":"2002","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.ejmech.2026.119341_bib16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejphar.2010.12.020","article-title":"Structure, function and regulation of the melanocortin receptors","volume":"660","author":"Yang","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119341_bib17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.jid.2021.06.018","article-title":"MC1R functions, expression, and implications for targeted therapy","volume":"142","author":"Guida","year":"2022","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejmech.2026.119341_bib18","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1134\/S0006297913110035","article-title":"Malignant melanoma and melanocortin 1 receptor","volume":"78","author":"Rosenkranz","year":"2013","journal-title":"Biochemistry. Biokhimiia"},{"key":"10.1016\/j.ejmech.2026.119341_bib19","article-title":"Melanocortin-1 receptor expression as a marker of progression in melanoma","volume":"8","author":"Su","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.ejmech.2026.119341_bib20","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1186\/s12967-023-04405-y","article-title":"Alpha-melanocyte stimulating hormone (\u03b1-MSH): biology, clinical relevance and implication in melanoma","volume":"21","author":"Dall'Olmo","year":"2023","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ejmech.2026.119341_bib21","series-title":"Handbook of Biologically Active Peptides","first-page":"689","article-title":"Chapter 96 - melanocortins","author":"J\u00e9gou","year":"2006"},{"key":"10.1016\/j.ejmech.2026.119341_bib22","doi-asserted-by":"crossref","first-page":"12152","DOI":"10.3390\/ijms241512152","article-title":"Melanocortin 1 receptor (MC1R): pharmacological and therapeutic aspects","volume":"24","author":"Mun","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119341_bib23","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.2967\/jnumed.118.217240","article-title":"Melanocortin 1 receptor\u2013targeted \u03b1-Particle therapy for metastatic uveal melanoma","volume":"60","author":"Tafreshi","year":"2019","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119341_bib24","doi-asserted-by":"crossref","first-page":"bqac083","DOI":"10.1210\/endocr\/bqac083","article-title":"The multifaceted melanocortin receptors","volume":"163","author":"Laiho","year":"2022","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejmech.2026.119341_bib25","doi-asserted-by":"crossref","DOI":"10.1186\/s41181-026-00473-9","article-title":"Synthesis and in vivo evaluation of a bifunctional, glutamic acid derived chelator for the 203\/212Pb theranostic pair","author":"Scaffidi-Muta","year":"2026","journal-title":"EJNMMI Radiopharmacy and Chemistry"},{"key":"10.1016\/j.ejmech.2026.119341_bib26","doi-asserted-by":"crossref","first-page":"8078","DOI":"10.1021\/jm201226w","article-title":"Development of melanoma-targeted polymer micelles by conjugation of a melanocortin 1 receptor (MC1R) specific ligand","volume":"54","author":"Barkey","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119341_bib27","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1021\/jm00018a005","article-title":"Cyclic lactam alpha-melanotropin analogues of Ac-Nle4-cyclo[Asp5, D-Phe7,Lys10] alpha-melanocyte-stimulating hormone-(4-10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors","volume":"38","author":"Hruby","year":"1995","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119341_bib28","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ejmech.2018.04.021","article-title":"Replacement of arg with Nle and modified D-Phe in the core sequence of MSHs, Ac-His-D-Phe-Arg-Trp-NH(2), leads to hMC1R selectivity and pigmentation","volume":"151","author":"Mowlazadeh Haghighi","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119341_bib29","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0960-894X(02)00830-2","article-title":"Structure\u2013activity relationship of linear peptide Bu-His-DPhe-Arg-Trp-Gly-NH2 at the human melanocortin-1 and -4 receptors: histidine substitution","volume":"13","author":"Cheung","year":"2003","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119341_bib30","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.jid.2020.11.034","article-title":"Development of hMC1R selective small agonists for sunless tanning and prevention of genotoxicity of UV in melanocytes","volume":"141","author":"Koikov","year":"2021","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejmech.2026.119341_bib31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/psc.1306","article-title":"A retro-inverso \u03b1-melanocyte stimulating hormone analog with MC1R-binding selectivity","volume":"17","author":"Weeden","year":"2011","journal-title":"J. Pept. Sci."},{"key":"10.1016\/j.ejmech.2026.119341_bib32","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1016\/S0960-894X(03)00552-3","article-title":"Sub-nanomolar hMC1R agonists by end-capping of the melanocortin tetrapeptide His-d-Phe-Arg-Trp-NH2","volume":"13","author":"Koikov","year":"2003","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119341_bib33","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1016\/j.bmcl.2004.05.039","article-title":"Analogs of sub-nanomolar hMC1R agonist LK-184 [Ph(CH2)3CO-His-d-Phe-Arg-Trp-NH2]. An additional binding site within the human melanocortin receptor 1?","volume":"14","author":"Koikov","year":"2004","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2026.119341_bib34","doi-asserted-by":"crossref","first-page":"5754","DOI":"10.1073\/pnas.77.10.5754","article-title":"4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity","volume":"77","author":"Sawyer","year":"1980","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejmech.2026.119341_bib35","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13550-019-0539-0","article-title":"A convenient and efficient total solid-phase synthesis of DOTA-functionalized tumor-targeting peptides for PET imaging of cancer","volume":"9","author":"Okarvi","year":"2019","journal-title":"EJNMMI Res."},{"key":"10.1016\/j.ejmech.2026.119341_bib36","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1021\/cr00078a006","article-title":"Reaction mechanisms in the radiolysis of peptides, polypeptides, and proteins","volume":"87","author":"Garrison","year":"1987","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2026.119341_bib37","series-title":"Encyclopedia of Radicals in Chemistry, Biology and Materials","article-title":"Oxidative damage to proteins","author":"Davies","year":"2012"},{"key":"10.1016\/j.ejmech.2026.119341_bib38","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1021\/bc034109i","article-title":"Ascorbic acid: useful as a buffer agent and radiolytic stabilizer for metalloradiopharmaceuticals","volume":"14","author":"Liu","year":"2003","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2026.119341_bib39","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.3390\/molecules28041884","article-title":"Radiolysis-associated decrease in radiochemical purity of 177Lu-Radiopharmaceuticals and comparison of the effectiveness of selected quenchers against this process","volume":"28","author":"Larenkov","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119341_bib40","first-page":"887","article-title":"Melanoma targeting with DOTA-\u03b1-Melanocyte-Stimulating hormone analogs: structural parameters affecting tumor uptake and kidney uptake","volume":"46","author":"Froidevaux","year":"2005","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119341_bib41","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1038\/s41401-022-00970-y","article-title":"MC1R and melanin-based molecular probes for theranostic of melanoma and beyond","volume":"43","author":"Shi","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2026.119341_bib42","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-54149-3","article-title":"Increase in negative charge of (68)Ga\/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules","volume":"9","author":"Rinne","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119341_bib43","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.drudis.2012.07.002","article-title":"Liver uptake of radiolabeled targeting proteins and peptides: considerations for targeting peptide conjugate design","volume":"17","author":"Hosseinimehr","year":"2012","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.119341_bib44","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2967\/jnumed.120.243840","article-title":"Advances in receptor-targeted radiolabeled peptides for melanoma imaging and therapy","volume":"62","author":"Miao","year":"2021","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119341_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2023.115374","article-title":"In vivo evaluation of newly synthesized 213Bi-conjugated alpha-melanocyte stimulating hormone (\u03b1-MSH) peptide analogues in melanocortin-1 receptor (MC1-R) positive experimental melanoma model","volume":"229","author":"K\u00e1lm\u00e1n-Szab\u00f3","year":"2023","journal-title":"J. Pharmaceut. Biomed. Anal."},{"key":"10.1016\/j.ejmech.2026.119341_bib46","doi-asserted-by":"crossref","first-page":"987","DOI":"10.2967\/jnumed.107.039602","article-title":"Small-animal PET of melanocortin 1 receptor expression using a 18F-Labeled \u03b1-Melanocyte-Stimulating hormone analog","volume":"48","author":"Cheng","year":"2007","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119341_bib47","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.cbpa.2021.06.008","article-title":"Reducing the renal retention of low- to moderate-molecular-weight radiopharmaceuticals","volume":"63","author":"Chigoho","year":"2021","journal-title":"Curr. Opin. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119341_bib48","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejphar.2010.11.040","article-title":"Melanocortin MC1 receptor in human genetics and model systems","volume":"660","author":"Beaumont","year":"2011","journal-title":"Eur. J. Pharmacol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426007865?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426007865?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:53:06Z","timestamp":1793922786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426007865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":48,"alternative-id":["S0223523426007865"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119341","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical evaluation of MC1R targeted radiopharmaceuticals using the 203\/212Pb theranostic pair","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119341","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119341"}}